Inovio Pharmaceuticals, Inc. Stock price

Equities

INO

US45773H4092

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
10.72 USD -0.14% Intraday chart for Inovio Pharmaceuticals, Inc. -10.96% +75.16%
Sales 2024 * 604K Sales 2025 * 8.03M Capitalization 251M
Net income 2024 * -99M Net income 2025 * -93M EV / Sales 2024 * 415 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 31.2 x
P/E ratio 2024 *
-2.78 x
P/E ratio 2025 *
-3.55 x
Employees 122
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.78%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform From Perform, $4 Price Target MT
Transcript : Inovio Pharmaceuticals, Inc. - Special Call
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment MT
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi) CI
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment MT
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from NASDAQ Biotechnology Index CI
Transcript : Inovio Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Inovio Shares Rise 8% After FDA Feedback for INO-3107 DJ
Inovio Pharmaceuticals Advised to File BLA for Drug Candidate to Treat Recurrent Respiratory Papillomatosis MT
Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107 CI
Inovio Says US FDA Breakthrough Therapy Designation Received for Recurrent Respiratory Papillomatosis Drug Candidate MT
More news
1 day-0.14%
1 week-10.96%
Current month+20.99%
1 month+35.18%
3 months+136.33%
6 months+122.22%
Current year+75.16%
More quotes
1 week
10.10
Extreme 10.1
12.62
1 month
7.08
Extreme 7.08
12.79
Current year
4.73
Extreme 4.73
12.79
1 year
3.89
Extreme 3.888
13.20
3 years
3.89
Extreme 3.888
124.92
5 years
3.89
Extreme 3.888
405.48
10 years
3.89
Extreme 3.888
405.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-03-24
Director of Finance/CFO 60 02-05-31
Chief Tech/Sci/R&D Officer - 07-01-31
Members of the board TitleAgeSince
Chairman 79 03-11-30
Director/Board Member 64 19-01-02
Director/Board Member 66 20-01-14
More insiders
Date Price Change Volume
24-03-18 10.72 -0.14% 333,404
24-03-15 10.74 -0.69% 312,279
24-03-14 10.81 -3.91% 338,002
24-03-13 11.25 -2.26% 934,767
24-03-12 11.51 -4.40% 598,731

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Inovio Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. The Company's lead candidates are focused on diseases associated with HPV. Its DNA medicines pipeline includes INO-3107 for HPV-related Recurrent Respiratory Papillomatosis (RRP), VGX-3100 for the treatment of HPV-related Cervical HSIL, INO-5401 for the treatment of Glioblastoma Multiforme (GBM), INO-5151 (INO-5150 + INO-9012) for the treatment of Prostate Cancer, INO-4800 for COVID-19, INO-4201 for Ebola Virus Disease, INO-4700 for Middle East Respiratory Syndrome (MERS) and INO-4500 for Lassa Fever. Its DNA medicine platform consists of DNA plasmids and its investigational smart device, CELLECTRA, which is used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of three models.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
10.72 USD
Average target price
19.25 USD
Spread / Average Target
+79.57%
Consensus
  1. Stock
  2. Equities
  3. Stock Inovio Pharmaceuticals, Inc. - Nasdaq